|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Medina PJ and Goodin S: Lapatinib: A dual
inhibitor of human epidermal growth factor receptor tyrosine
kinases. Clin Ther. 30:1426–1447. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Blackwell KL, Kaplan EH, Franco SX, Marcom
PK, Maleski JE, Sorensen MJ and Berger MS: A phase II, open-label,
multicenter study of GW572016 in patients with
trastuzumab-refractory metastatic breast cancer. Proc Ann Meeting
Am Soc Clin Oncol. 23:1962004.
|
|
6
|
Geyer CE, Forster J, Lindquist D, Chan S,
Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A,
Kaufman B, et al: Lapatinib plus capecitabine for HER2-positive
advanced breast cancer. N Engl J Med. 355:2733–2743. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Johnston PG, Drake JC, Trepel J and
Allegra CJ: Immunological quantitation of thymidylate synthase
using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive
and -resistant human cancer cell lines. Cancer Res. 52:4306–4312.
1992.PubMed/NCBI
|
|
8
|
Johnston PG, Fisher ER, Rockette HE,
Fisher B, Wolmark N, Drake JC, Chabner BA and Allegra CJ: The role
of thymidylate synthase expression in prognosis and outcome of
adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol.
12:2640–2647. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tanizaki J, Okamoto I, Takezawa K,
Tsukioka S, Uchida J, Kiniwa M, Fukuoka M and Nakagawa K:
Synergistic antitumor effect of S-1 and HER2-targeting agents in
gastric cancer with HER2 amplification. Mol Cancer Ther.
9:1198–1207. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yasui K, Okamoto H, Arii S and Inazawa J:
Association of over-expressed TFDP1 with progression of
hepatocellular carcinomas. J Hum Genet. 48:609–613. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nakajima T, Yasui K, Zen K, Inagaki Y,
Fujii H, Minami M, Tanaka S, Taniwaki M, Itoh Y, Arii S, et al:
Activation of B-Myb by E2F1 in hepatocellular carcinoma. Hepatol
Res. 38:886–895. 2008.PubMed/NCBI
|
|
12
|
Gschwantler-Kaulich D, Grunt TW, Muhr D,
Wagner R, Kölbl H and Singer CF: HER Specific TKIs exert their
antineoplastic effects on breast cancer cell lines through the
involvement of STAT5 and JNK. PLoS One. 11:e01463112016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ludyga N, Anastasov N,
Gonzalez-Vasconcellos I, Ram M, Höfler H and Aubele M: Impact of
protein tyrosine kinase 6 (PTK6) on human epidermal growth factor
receptor (HER) signalling in breast cancer. Mol Biosyst.
7:1603–1612. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
DeGregori J, Kowalik T and Nevins JR:
Cellular targets for activation by the E2F1 transcription factor
include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol.
15:4215–4224. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baselga J, Cortés J, Kim SB, Im SA, Hegg
R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al:
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast
cancer. N Engl J Med. 366:109–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hurvitz SA, Dirix L, Kocsis J, Bianchi GV,
Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, et al: Phase II
randomized study of trastuzumab emtansine versus trastuzumab plus
docetaxel in patients with human epidermal growth factor receptor
2-positive metastatic breast cancer. J Clin Oncol. 31:1157–1163.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hallstrom TC and Nevins JR: Specificity in
the activation and control of transcription factor E2F-dependent
apoptosis. Proc Natl Acad Sci USA. 100:10848–10853. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu K, Paik JC, Wang B, Lin FT and Lin WC:
Regulation of TopBP1 oligomerization by Akt/PKB for cell survival.
EMBO J. 25:4795–4807. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Blackstein M, Vogel CL, Ambinder R, Cowan
J, Iglesias J and Melemed A: Gemcitabine as first-line therapy in
patients with metastatic breast cancer: A phase II trial. Oncology.
62:2–8. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Curigliano G, Cardinale D, Suter T,
Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch
A, Cipolla C and Roila F: ESMO Guidelines Working Group:
Cardiovascular toxicity induced by chemotherapy, targeted agents
and radiotherapy: ESMO clinical practice guidelines. Ann Oncol. 23
Suppl 7:vii155–vii166. 2012. View Article : Google Scholar : PubMed/NCBI
|
